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ABSTRACT  
Background: In multiple sclerosis(MS), diffusion tensor and 
magnetisation transfer(MT) imaging are both abnormal in lesional and 
extra-lesional cortical grey matter(GM), but differences between clinical 
subtypes and associations with clinical outcomes have only been partly 
assessed. 
Objective: To compare mean diffusivity(MD), fractional anisotropy(FA), 
MT ratio(MTR) in cortical GM lesions(detected using phase-sensitive 
inversion recovery(PSIR) imaging) and extra-lesional cortical GM, and 
assess associations with disability in relapse-onset MS. 
Methods: Seventy-two people with MS(46 relapsing-remitting(RR), 26 
secondary-progressive(SP)) and 36 healthy controls were included in this 
study. MTR, MD and FA were measured in lesional and extra-lesional 
cortical GM. 
Results: Mean FA was higher and MTR lower in lesional compared with 
extra-lesional cortical GM. In extra-lesional cortical GM mean FA and MTR 
were lower, and MD higher in the MS group compared with controls. Mean 
MTR was lower and MD higher in lesional and extra-lesional cortical GM in 
SPMS when compared with RRMS. These differences were independent of 
disease duration. In multivariate analyses, MTR in extra-lesional more so 
than lesional cortical GM was associated with disability. 
Conclusion: MR abnormalities in lesional and extra-lesional cortical GM 
are greater in SPMS than RRMS. Changes in extra-lesional compared with 
lesional cortical GM are more consistently associated with disability. 
INTRODUCTION
Cortical grey matter (GM) pathology can be substantial in multiple 
sclerosis (MS) and is recognised as a major factor contributing to 
neurological and cognitive disability. Cortical demyelinating lesions are 
seen after the first symptomatic episode in people who later develop MS, 
and extensive cortical lesions found in people with progressive MS 
subtypes.1–5 Extra-lesional (sometimes described as 'normal appearing') 
cortical GM is also abnormal, with reductions in both neuronal and 
oligodendrocyte densities reported.6  
Few in vivo studies have compared cortical lesion features between MS 
clinical subtypes. Using double inversion recovery (DIR) obtained at 1.5T 
Calabrese et al. found that cortical GM lesions were significantly more 
numerous and extensive in SPMS than RRMS.7 Using a 3T MRI system, we 
confirmed this using DIR and phase-sensitive inversion recovery (PSIR) 
imaging.8 Both magnetisation transfer (MT) imaging and diffusion tensor 
imaging (DTI) measures are abnormal in lesional compared with extra-
lesional GM,13,14,29 but there are only two in-vivo studies investigating 
differences in MTI and DTI characteristics of GM lesions between RRMS 
and SPMS.14,29 
Abnormalities in extra-lesional GM have been found in vivo using 
MTI 10–12 and DTI.13,14 However, extra-lesional GM defined on MRI is not 
the same as extra-lesional GM examined in histopathological studies. Of 
histopathologically confirmed intracortical lesions (lesions only involving 
cortical GM), 5% or less are detected using proton density (PD)/T2-
weighted scans obtained at 1.5T 30 and with DIR scans at 1.5T about 10% 
are identified.30 As such, most cortical GM lesions will fall within MRI-
defined extra-lesional GM, and both GM lesions and abnormalities within 
truly extra-lesional GM may contribute to the MT and DTI abnormalities 
previously found in MRI-defined extra-lesional GM.10-14 In previous work 
aiming to improve GM lesion detection, we found about three times as 
many intracortical GM lesions on the PSIR compared with DIR scans, both 
obtained using the same 3T MRI machine in the same subjects. PSIR has 
not previously been used to define lesional and extra-lesional GM, but 
should yield a substantially larger sample of cortical GM lesions, and 
reduce contamination of MRI-defined extra-lesional GM by unseen lesions, 
when compared with studies using either PD/T2-weighted or DIR scans to 
detect GM lesions. 
In this study we investigated lesional and extra-lesional cortical GM 
abnormalities in RRMS and SPMS, and their relationship with disability. To 
achieve this, we used a combination of MRI techniques: PSIR to detect 
cortical lesions,15 high-resolution MTR (sensitive to GM demyelination),16 
and DTI to assess tissue structural integrity. To avoid contamination of 
GM lesion measures by WM, we confined our analysis to intracortical GM 
lesions. 17 We addressed two questions:  
1. Is lesional and extra-lesional cortical GM more abnormal in SPMS
compared with RRMS? 
2. Is neurological and cognitive disability in MS more closely related to
abnormalities in lesional or extra-lesional cortical GM? 
METHODS
Participants were between 18 and 65 years old, and had a diagnosis of 
clinically definite MS according to McDonald criteria.18 The control group 
had no known neurological disease. MS subtypes were classified using the 
Lublin-Reingold criteria.19 All participants gave written informed consent. 
This study was approved by our local institutional ethics committee. 
Participants 
We included 72 people with MS and 36 healthy control subjects. 
Demographic details are given in Table 1. 
Clinical assessments 
Expanded Disability Status Scale (EDSS),20 MS Functional Composite 
(MSFC),21 and Symbol Digit Modalities Test (SDMT)22 scores were 
determined. MSFC and SDMT scores were also obtained from controls. 
Image acquisition 
Using a 3T Philips Achieva system (Philips Healthcare, Best, The 
Netherlands) with a 32-channel head coil and multi-transmit technology, 
the following sequences were acquired: T1-weighted volumetric, PSIR, 
PD/T2-weighted, fluid attenuated inversion recovery (FLAIR), DTI, and 
MTR. Acquisition parameters are given in supplemental eTable 1.  
MRI analysis 
Lesion identification 
Cortical lesions confined to GM (intracortical lesions) were outlined on 
PSIR images using JIM (Version 6.0, Xinapse Systems, Northants) and 
their volume calculated (Figure 1). As in previous work, PD/T2-weighted 
and FLAIR-scans were used for reference.8 White matter (WM) lesions 
were identified using the PD/T2-weighted scans. Marking of all scans was 
carried out blinded to clinical data by OY and VS, under the guidance of 
TY, an expert neuroradiologist. 
Generation of the cortex and white matter masks 
Registrations were carried out using NitfyReg.23,24 PSIR images with their 
corresponding lesion masks were affine registered to the T1-weighted 
volumetric images. After lesion filling 25, the T1-weighted volume images 
were segmented using SPM8 (Wellcome Trust Centre for Neuroimaging, 
London, UK) and voxels with a ≥95% probability of being GM were 
included in the GM masks used in subsequent analyses. The Montreal 
Neurological Institute (MNI)-152 T1-template was segmented using SPM8, 
and the supratentorial cortex was manually extracted from the GM map 
using FSL (Functional magnetic resonance imaging of the brain Software 
Library, Oxford, UK). The MNI-152 template was affine registered to each 
subject’s T1-weighted volume image, and a cortical GM mask prepared by 
extracting only GM voxels that fell within both the thresholded SPM8 
segmentation of the T1-weighted image and the MNI-derived cortical 
mask. A mask of extra-lesional cortical GM was obtained subtracting the 
PSIR-derived cortical lesion mask from the cortical GM mask. A NAWM 
mask was prepared by thresholding the SPM8 WM probability maps at 
95%, and subtracting WM lesions detected on the PD/T2-weighted scan. 
Using the SPM8 segmentations of the lesion-filled T1-weighted volume 
images, brain parenchymal fraction (BPF) was calculated by dividing the 
sum of GM and WM volume by the total intracranial volume.38 
Diffusion tensor imaging processing 
Diffusion-weighted images were registered to the non-diffusion-weighted 
(b0) images and eddy current corrected using FSL. For each subject a 
mean b0-image was created by averaging the seven b0-images acquired. 
Fractional anisotropy (FA) and mean diffusivity (MD) maps were 
generated using Camino.26 For each subject, the DTI-scans were 
registered to the T1-weighted volumetric images via a pseudo (p)T1-
weighted image generated from the PD/T2-weighted scan.27 The mean 
b0-image was registered to the pT1-image using first affine and then non-
linear transformations. The pT1-image was registered to the T1-weighted 
volumetric scan using a rigid-body registration. The b0-to-pT1 and pT1-
to-T1 transformations were combined, bringing the b0-images (and the 
associated MD and FA maps) into alignment with the T1-weighted 
volumetric scans. 
Magnetisation transfer imaging processing 
MT(on) and MT(off) images for each subject were affine registered to their 
T1-weighted volume scan. MT ratio (R) was calculated for each voxel as 
S(0)-S(RF)/S(0), where S(0) and S(RF) are the signal intensities without 
and with the application of the off-resonance pulse. 
Lesional and extra-lesional cortical grey matter quantitative MRI measures 
With the MTR and DTI maps, and lesion and tissue masks aligned with the 
T1-weighted volumetric scans, FA, MD and MTR measures were extracted 
from each of the masked regions.  
Quality assessment 
The MT and diffusion images were reviewed for artefacts, for example 
associated with subject motion, by OY. Every registration step for every 
image was reviewed by OY for accuracy. The segmented T1-weighted 
images were also reviewed for quality by OY. The registration steps and 
images of every tenth patient were re-reviewed by DTC for artefacts, 
registration and segmentation quality. 
Statistical analysis 
Continuous data are presented as mean±standard deviation. EDSS scores 
are presented as median (range). There was evidence of non-normality in 
FA, MD and MTR in lesional GM, FA and MD in extra-lesional GM, and 
cortical lesion volume measures (all p<0.05, Shapiro-Wilk test). 
Associations between age, disease duration and quantitative MRI-
measures were investigated using Spearman correlation. The differences 
in cortical lesion count and volume between RRMS and SPMS were 
investigated using Mann-Whitney tests. General linear model was used to 
determine if MTR and DTI measures differed between subject groups, with 
age and disease duration as covariates. All group comparisons were 
confirmed by bootstrap analysis (case resampling, n=1000). The Wilcoxon 
Signed-rank test was used to compare MTR and DTI measures in lesional 
and extra-lesional GM in the subgroups. 
Associations between clinical (EDSS, MSFC and SDMT scores) and 
MRI measures (lesional and extra-lesional GM MTR and DTI, PD/T2-
weighted lesion volumes and BPF) were investigated using Spearman 
correlation, and further explored using a stepwise linear regression model 
including all significant MRI variables from the univariate analysis as 
covariates confirmed by bootstrap analysis (case resampling, n=1000). 
Adjusted R-square values are given for each significant covariate. MSFC 
scores were transformed into z-scores with reference to the control group. 
Given the problems associated with formally correcting for multiple 
comparisons28 we present results flagged using the conventional (p<0.05) 
significance threshold. We used SPSS (Version 21, Chicago, IL, USA) for 
the statistical analysis.  
RESULTS
Age and gender effects 
We did not find any association between sex and MTR and DTI measures 
in cortical GM in controls, or lesional or extra-lesional GM in people with 
MS. Age correlated with lesional GM MTR and BPF in MS, and with BPF in 
controls (all p<0.05, Spearman correlations). 
Cortical grey matter lesions 
Compared with people with RRMS those with SPMS had higher median 
intracortical lesion counts and volumes (Table 2). 
MRI abnormalities in extra-lesional cortical grey matter 
In extra-lesional cortical GM, mean MTR and FA were lower in MS 
compared with the controls, while mean MD was higher in the MS group 
than controls (all p<0.001, general linear model). Mean MTR was lower in 
the SPMS than RRMS groups (p<0.05), and remained so after adjusting 
for age, disease duration and extra-lesional cortical GM mask volume 
(p<0.05). There was a trend to higher MD in SPMS than RRMS, but FA did 
not differ significantly (Table 2). Disease duration correlated with FA, MD 
and MTR in extra-lesional cortical GM (all p<0.05, Spearman correlation) 
but this was not significant in a multivariate linear regression model when 
MS subtype was also included. MTR results are illustrated in Figure 2. For 
completeness, mean MTR, FA and MD values in the whole cortex, 
leucocortical lesions (those including both GM and WM), PD/T2 WM lesions 
and NAWM are given in supplemental eTable 2. 
MRI abnormalities in cortical grey matter lesions  
In the combined MS group, FA was higher and MD lower in cortical lesions 
when compared with extra-lesional cortical GM (both p<0.001, Wilcoxon 
Signed-rank test). The greatest difference in FA and MD was seen in 
people with SPMS. In SPMS, cortical lesion MTR was lower than in extra-
lesional cortical GM (p=0.03, Wilcoxon Signed-rank test). In people with 
RRMS, lesional and extra-lesional cortical GM MTR did not differ 
significantly (Figure 2). 
In SPMS compared with RRMS mean MTR was lower and mean MD higher 
in cortical GM lesions (both p<0.01, Table 2), and this remained 
significant after adjusting for age, disease duration, extra-lesional cortical 
GM mask volume and cortical GM lesion volume (all p<0.05). In contrast, 
mean FA in cortical GM lesions did not differ significantly between RRMS 
and SPMS. Disease duration correlated with MD and MTR in cortical GM 
lesions (both p<0.05, Spearman correlation) but this association was not 
significant in a multivariable linear regression model when disease 
subtype was also included in the model. 
Associations of MRI measures with disability scores 
In the combined MS-group the following associations were observed (all 
p<0.05, supplemental eTable 3): 
(1) EDSS scores correlated with MD and MTR in lesional and extra-lesional 
cortical GM, and with BPF 
(2) MSFC scores correlated with extra-lesional GM MD and MTR, lesional 
GM MTR, PD/T2-lesion volume and BPF 
(3) SDMT scores correlated with FA, MD and MTR in extra-lesional cortical 
GM, MTR in GM lesions, PD/T2-lesion volume and BPF.  
In a multivariable linear regression model (including all the variables 
found to significantly correlate with EDSS, MSFC or SDMT), extra-lesional 
cortical GM MTR was most consistently associated with clinical outcome 
measures (Table 3). The same was found for mean MTR in the whole 
cortex (supplemental eTable 4).  
DISCUSSION
In this study we found that MTR and MD were both more abnormal in 
cortical GM lesions in SPMS than RRMS, and MTR was also more abnormal 
in extra-lesional cortical GM in SPMS compared with RRMS. These 
differences were independent of disease duration, suggesting that SPMS 
per se is characterised by more marked cortical GM pathology. Of the MRI 
measures included in this work, MTR in extra-lesional cortical GM emerged 
as being most consistently correlated with clinical outcome measures.  
To the best of our knowledge, there has only been one previous in 
vivo study on MTR in cortical GM lesions in a mixed group of people with 
RRMS and SPMS, using DIR scans obtained with a 1.5T MRI system to 
identify lesions.29 This demonstrated a relative reduction in MTR in lesional 
compared with extra-lesional GM. Our study, using PSIR obtained at 3T to 
identify and classify cortical lesions (and so, when compared with DIR, 
less likely to inadvertently include WM lesions9), confirms that MTR is 
reduced in GM lesions when compared with extra-lesional GM, and builds 
on this by demonstrating that a reduction in MTR is more apparent in 
SPMS than RRMS (Figure 2). However, it should be recalled that while the 
majority of cortical lesions are subpial1, these are very rarely detected 
using DIR30 or PSIR8, and so it cannot be assumed that the results of the 
present study are representative of subpial GM lesions.  
Previous in vivo work using DIR at 1.5T to identify cortical lesions 
has shown lower MD and higher FA values relative to extra-lesional 
cortical GM.14 A relatively higher FA is contrary to changes seen in WM 
lesions (in which FA is decreased14). In recent work we found that nearly a 
third of intracortical lesions (lesions confined to GM alone) identified on 
DIR appeared to involve WM when viewed on a PSIR scan9. This raises the 
possibility that previous GM lesion findings may in part have been due to 
WM contamination (which has a higher FA than GM14). However, the 
present results, obtained using PSIR, confirm previous observations. This 
suggests that partial volume alone does not explain the high FA values in 
cortical GM lesions. The reason for higher FA and lower MD in cortical 
lesions relative to extra-lesional GM is not known. One possible 
explanation comes from a study on the preterm human cortex which 
found that FA values are high at 26 weeks of gestational age, when the 
pyramidal cells have prominent apical dendrites radially oriented 
perpendicular to the pial surface, and in the subsequent weeks FA 
declines, which coincides with the development of basal dendrites.32 In 
cortical GM lesions the dendritic arbor is damaged6, which may result in a 
reversal of FA changes associated with normal cortical development, i.e. 
an increase in FA. 
We found that cortical lesion MTR was significantly lower in SPMS 
than RRMS. While disease duration correlated with cortical lesion MTR, 
this association was lost once the MS phenotype was included in the 
statistical model, suggesting that the greater reduction in MTR seen in 
SPMS is not simply the result of a having had MS longer, but that SPMS is 
itself associated with greater abnormalities. This is consistent with 
previous work on WM lesions, which are known to be more intensely 
abnormal in SPMS compared with RRMS: Filippi et al. demonstrated that 
the ratio of T1-hypointense to PD/T2-weighted lesions varied markedly 
between MS subtypes, being higher in SPMS (0.24) than RRMS (0.12).33
Our extra-lesional cortical GM findings also agree with previous work 
investigating MTR and diffusion MRI features.13 As with cortical GM lesions, 
we found that MTR in extra-lesional GM was reduced in the MS group when 
compared with controls, and this reduction was greater in SPMS compared 
with RRMS. In extra-lesional GM we found a lower FA and higher MD in the 
MS group compared with controls, which is consistent with most,14,34–36 but 
not all previous studies on cortical GM diffusion.13 While there was a trend 
to a higher MD in extra-lesional GM in SPMS compared with RRMS, this did 
not reach statistical significance. Recalling that even using PSIR it is likely 
that only a minority of cortical lesions will be seen, these results may 
partly reflect the effects of unseen lesions. However, the discrepant FA 
abnormalities in cortical lesions (increased) and extra-lesional cortical GM 
(decreased) suggest that not all changes in extra-lesional GM can be 
explained by undetected GM lesions. This is also supported by 
histopathological studies which have shown reductions in oligodendrocyte 
and neuronal densities in extra-lesional GM, both of which may lead to 
alterations in MTR and diffusion MRI measures.6,37 Pathological 
interpretation of MTR and DTI abnormalities in cortical GM is difficult as 
there have only been two combined MRI and histopathological studies of 
cortical MTR in MS, demonstrating associations between 
reduced MTR and cortical demyelination, and no studies assessing the 
pathological substrates of diffusion abnormalities.16,17
Physical and cognitive disability, as measured using EDSS, SDMT 
and MSFC, were associated both with abnormalities in lesional and extra-
lesional cortical GM albeit with relatively modest strengths. However, in 
the regression models only changes in extra-lesional GM consistently 
associated with EDSS, SDMT and MSFC. This is perhaps not surprising 
considering that the majority of GM is extra-lesional, and so likely to 
contribute more of the overall pathological burden of MS than GM lesions. 
In addition, a substantial proportion of GM lesions (and virtually all subpial 
lesions) will go undetected using DIR or PSIR, and so be included in MRI-
based extra-lesional GM measures. 
In addition to those noted above, there are a few other study limitations 
worth mentioning. The cortex is only 3-5 mm thick, and convoluted, and 
so partial volume may affect the results. Given that the MTR data was 
acquired at 1x1x1mm3 and the diffusion data at 2x2x2mm3, partial 
volume effects are more likely to influence DTI rather than the MTR 
results, although we used a conservative segmentation method to limit 
this, and included the cortical GM volume as a factor in the statistical 
model as an extra precaution. We assessed intracortical rather than 
leucocortical lesions to avoid contamination from WM, however a 
combined analysis of the intracortical lesions and the GM part of 
leucocortical lesions yielded similar results (see supplemental Table e2). 
       In this multimodal MRI study, it has been necessary to register each 
subject’s MTR, DTI, PSIR and PD/T2-weighted scans to their T1-weighted 
volumetric scans. These registrations may still leave images very slightly 
out of alignment (each set of scans were checked for visible 
misalignment) and re-sampling the images will also add a small amount of 
noise. This noise will be random and, as the same methods were used in 
all subjects, should not lead to spurious differences between the groups or 
associations with clinical outcome measures being introduced. However, 
additional random noise may have reduced sensitivity to group differences 
and the apparent strength of correlations with clinical outcomes. When 
comparing the results of the present work with previous studies, it should 
be recalled that the MRI measures in this study produce method specific 
rather than method independent values. As such we cannot directly 
compare the absolute values of the MRI measures from this study with 
those produced using a different scanner or scan protocol, although 
relative differences between tissue types should be consistent. It should 
also be noted that the SPMS group was smaller than the RRMS group. This 
will have resulted in there being less statistical power when analysing the 
SPMS group data, and so relative to results from the RRMS group, we may 
have underestimated the significance of differences between the SPMS 
group and either the control or RRMS groups, and associations of MRI 
measures with clinical outcomes. Lastly, while we have found statistically 
significant differences in MTR and diffusion measures between MS groups, 
there is considerable overlap between them; on a person-by-person basis, 
reliable separation into RRMS and SPMS groups could not be achieved 
using these methods. 
In conclusion, we have found that MTR and DTI measures in lesional 
and extra-lesional cortical GM differ between RRMS and SPMS. This 
suggests that not only are cortical lesions more extensive in people with 
SPMS compared with RRMS, but also that the intensity of pathological 
changes in lesional and extra-lesional GM may be greater. The intensity of 
pathology (as measured using MTR) was not accounted for by disease 
duration alone, suggesting that a SPMS compared with RRMS course is 
associated with greater GM abnormalities. Disability scores correlated 
more consistently with extra-lesional (and whole cortical) GM measures 
than cortical lesion measures, and so in clinical studies of RRMS and SPMS 
assessing MRI features of the whole cortex rather lesions may be more 
useful. 
References 
1. Bo L, Vedeler CA, Nyland HI, Trapp BD, Mork SJ. Subpial demyelination
in the cerebral cortex of multiple sclerosis patients. J Neuropathol Exp
Neurol 2003;62:723-32.
2. Calabrese M, De Stefano N, Atzori M, et al. Detection of cortical
inflammatory lesions by double inversion recovery magnetic resonance
imaging in patients with multiple sclerosis. Arch Neurol 2007;64:1416-
22. doi:64/10/1416 [pii] 10.1001/archneur.64.10.1416.
3. Geurts JJ, Calabrese M, Fisher E, Rudick RA. Measurement and clinical
effect of grey matter pathology in multiple sclerosis. Lancet Neurol
2012;11:1082-92. doi:S1474-4422(12)70230-2 [pii] 10.1016/S1474-
4422(12)70230-2.
4. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical
demyelination and diffuse white matter injury in multiple sclerosis.
Brain 2005;128:2705-12. doi:awh641 [pii] 10.1093/brain/awh641.
5. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites,
apoptotic neurons, and reduced inflammation in cortical multiple
sclerosis lesions. Ann Neurol 2001;50:389-400.
6. Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss
and meningeal inflammation in multiple sclerosis. Ann Neurol
2010;68:477-93. doi:10.1002/ana.22230.
7. Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load
associates with progression of disability in multiple sclerosis. Brain
2012;135:2952-61. doi:aws246 [pii] 10.1093/brain/aws246.
8. Sethi V, Yousry TA, Muhlert N, et al. Improved detection of cortical MS
lesions with phase-sensitive inversion recovery MRI. J Neurol
Neurosurg Psychiatry 2012;83:877-82. doi:jnnp-2012-303023 [pii]
10.1136/jnnp-2012-303023.
9. Sethi V, Muhlert N, Ron M, et al. MS cortical lesions on DIR: not quite
what they seem? PLoS One 2013;8:e78879.
doi:10.1371/journal.pone.0078879 PONE-D-13-24222 [pii].
10. Cercignani M, Bozzali M, Iannucci G, Comi G, Filippi M.
Magnetization transfer ratio and mean diffusivity of normal appearing 
white and grey matter from patients with multiple sclerosis. J Neurol 
Neurosurg Psychiatry 2001;70:311-7. 
11. Dehmeshki J, Chard DT, Leary SM, et al. The normal appearing grey
matter in primary progressive multiple sclerosis: a magnetization 
transfer imaging study. J Neurol 2003;250:67-74. 
doi:10.1007/s00415-003-0955-x. 
12. Ramio-Torrenta L, Sastre-Garriga J, Ingle GT, et al. Abnormalities in
normal appearing tissues in early primary progressive multiple 
sclerosis and their relation to disability: a tissue specific magnetization 
transfer study. J Neurol Neurosurg Psychiatry 2006;77:40-5. 
doi:77/1/40 [pii] 10.1136/jnnp.2004.052316. 
13. Calabrese M, Rinaldi F, Seppi D, et al. Cortical diffusion-tensor
imaging abnormalities in multiple sclerosis: a 3-year longitudinal study. 
Radiology 2011;261:891-8. doi:radiol.11110195 [pii] 
10.1148/radiol.11110195. 
14. Filippi M, Preziosa P, Pagani E, et al. Microstructural magnetic
resonance imaging of cortical lesions in multiple sclerosis. Mult Scler 
2013;19:418-26. doi:1352458512457842 [pii] 
10.1177/1352458512457842. 
15. Nelson F, Poonawalla AH, Hou P, Huang F, Wolinsky JS, Narayana
PA. Improved identification of intracortical lesions in multiple sclerosis 
with phase-sensitive inversion recovery in combination with fast double 
inversion recovery MR imaging. AJNR Am J Neuroradiol 2007;28:1645-
9. doi:ajnr.A0645 [pii] 10.3174/ajnr.A0645.
16. Chen JT, Easley K, Schneider C, et al. Clinically feasible MTR is
sensitive to cortical demyelination in MS. Neurology 2013;80:246-52. 
doi:WNL.0b013e31827deb99 [pii] 10.1212/WNL.0b013e31827deb99. 
17. Schmierer K, Wheeler-Kingshott CA, Boulby PA, et al. Diffusion
tensor imaging of post mortem multiple sclerosis brain. Neuroimage 
2007;35:467-77. doi:S1053-8119(06)01198-0 [pii] 
10.1016/j.neuroimage.2006.12.010. 
18. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for
multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann 
Neurol 2005;58:840-6. doi:10.1002/ana.20703. 
19. Lublin FD, Reingold SC. Defining the clinical course of multiple
sclerosis: results of an international survey. National Multiple Sclerosis 
Society (USA) Advisory Committee on Clinical Trials of New Agents in 
Multiple Sclerosis. Neurology 1996;46:907-11. 
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology 1983;33:1444-52. 
21. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple
sclerosis functional composite as a clinical trial outcome measure. 
Brain 1999;122 ( Pt 5):871-82. 
22. Smith A. Symbol Digit Modalities Test. Los Angeles; 1982.
23. Modat M, Ridgway GR, Taylor ZA, et al. Fast free-form deformation
using graphics processing units. Comput Methods Programs Biomed 
2010;98:278-84. doi:S0169-2607(09)00253-3 [pii] 
10.1016/j.cmpb.2009.09.002. 
24. Ourselin S, Roche A, Subsol G, Pennec X, Ayache N. Reconstructing
a 3D structure from serial histological sections. Image Vis. Comput. 
2001;19:25-31. 
25. Chard DT, Jackson JS, Miller DH, Wheeler-Kingshott CA. Reducing
the impact of white matter lesions on automated measures of brain 
gray and white matter volumes. J Magn Reson Imaging 2010;32:223-
8. doi:10.1002/jmri.22214.
26. Cook PA, Bai Y, Nedjati-Gilani S, et al. Camino: Open-Source
Diffusion-MRI Reconstruction and Processing. 14th Sci. Meet. Int. Soc. 
Magn. Reson. Med. Seattle WA USA 2006:2759. 
27. Hickman SI, Barker GJ, Molyneux PD, Miller DH. Technical note: the
comparison of hypointense lesions from “pseudo-T1” and T1-weighted 
images in secondary progressive multiple sclerosis. Mult Scler 
2002;8:433-5. 
28. Perneger TV. What’s wrong with Bonferroni adjustments. BMJ
1998;316:1236-8. 
29. Papadopoulou A, Amann M, Andelova M, et al. A magnetization
transfer ratio (MTR) study of cortical lesions in multiple sclerosis as 
assessed with high-resolution MT imaging. Mult Scler J. 2013;19:74-
558. 
30. Seewann A, Kooi EJ, Roosendaal SD, et al. Postmortem verification
of MS cortical lesion detection with 3D DIR. Neurology 2012;78:302-8. 
doi:WNL.0b013e31824528a0 [pii] 10.1212/WNL.0b013e31824528a0. 
31. Samson RS, Cardoso MJ, Muhlert N, et al. Investigation of outer
cortical magnetization transfer ratio abnormalities in multiple sclerosis 
clinical subgroups. Mult Scler 2014. doi:1352458514522537 [pii] 
10.1177/1352458514522537. 
32. McKinstry RC, Mathur A, Miller JH, et al. Radial organization of
developing preterm human cerebral cortex revealed by non-invasive 
water diffusion anisotropy MRI. Cereb Cortex 2002;12:1237-43. 
33. Filippi M, Iannucci G, Tortorella C, et al. Comparison of MS clinical
phenotypes using conventional and magnetization transfer MRI. 
Neurology 1999;52:588-94. 
34. Bozzali M, Cercignani M, Sormani MP, Comi G, Filippi M.
Quantification of brain gray matter damage in different MS phenotypes 
by use of diffusion tensor MR imaging. AJNR Am J Neuroradiol 
2002;23:985-8. 
35. Rovaris M, Bozzali M, Iannucci G, et al. Assessment of normal-
appearing white and gray matter in patients with primary progressive 
multiple sclerosis: a diffusion-tensor magnetic resonance imaging 
study. Arch Neurol 2002;59:1406-12. doi:noc20062 [pii]. 
36. Vrenken H, Pouwels PJ, Geurts JJ, et al. Altered diffusion tensor in
multiple sclerosis normal-appearing brain tissue: cortical diffusion 
changes seem related to clinical deterioration. J Magn Reson Imaging 
2006;23:628-36. doi:10.1002/jmri.20564. 
37. Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical
neuronal, synaptic, and glial loss in multiple sclerosis. Neurology 
2006;67:960-7. doi:67/6/960 [pii] 
10.1212/01.wnl.0000237551.26858.39. 
38. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain
      parenchymal fraction to measure whole brain atrophy in relapsing-
remitting MS.    
      Multiple Sclerosis Collaborative Research Group. Neurology. 1999; 
53(8):1698– 
      1704. 
Acknowledgments 
We thank all the people who participated in this study and Daniel Altmann 
for statistical support. 
Conflicts of interest 
ÖY received honoraria for lectures from Teva and Bayer Schering (paid to 
University Hospital Basel).  
VS received research support from Biogen Idec and Novartis.  
NM reports no disclosures.  
MP is supported by the non-profit Karol Wojtila Association (Lavagna, 
Italy) and received research support from Novartis.  
LZ has received research funding from the European Committee for 
Treatment and Research in Multiple Sclerosis.  
TY serves as Editor for European Radiology Journal and has received 
honoraria (Board Membership) from UCB, Bristol-Myers Squibb, Biogen 
Idec, and grants (PI or Co-PI Coordinator) from NIHR CBRC, MRC, MS 
Society, PSP, Stroke, BHF, Wellcome Trust, GSK, Biogen Idec, Novartis.  
DJT reports no disclosures.  
RS reports no disclosures.  
CWK is on the advisory board for BG12 (Biogen) and is serving as co-
editor for Functional Neurology. 
DHM has received honoraria from Biogen Idec, Novartis, GlaxoSmithKline, 
and Bayer Schering, and research grant support for doing MRI analysis in 
multiple sclerosis trials sponsored by GlaxoSmithKline, Biogen Idec and 
Novartis.  
DTC has received honoraria (paid to UCL) from Bayer, Teva and the 
Serono Symposia International Foundation for faculty-led education work, 
Teva for advisory board work, and holds stock in GlaxoSmithKline. 
Funding 
This study was funded by the MAGNIMS / ECTRIMS and the University of 
Basel, Switzerland.  
The NMR Research Unit is supported by the MS Society of Great Britain 
and Northern Ireland and the UCL UCLH Comprehensive Biomedical 
Research Centre. The MS Society of Great Britain and Northern Ireland 
has provided financial support for staff and research costs (grant 917-09). 
Participant's  consent 
Informed consent form approved by local ethics committee (London 
Queen Square R.E.C) was used for this project and signed by every 
participant. 
Ethics approval 
London Queen Square REC. 
Authors contributions: 
Dr Özgür Yaldizli had full access to all of the data in the study and takes 
responsibility for the integrity of the data and the accuracy of the data 
analysis.  
Study concept and design: Dr Özgür Yaldizli, Dr Declan T Chard, Dr 
Matteo Pardini, Dr Varun Sethi, Dr Zheng Liu, Dr Claudia Wheeler-
Kingshott, Prof David H Miller.  
Acquisition of data: Dr Özgür Yaldizli, Dr Varun Sethi, Dr Nils Muhlert, Dr 
Declan T Chard.  
Analysis and interpretation of data: Dr Özgür Yaldizli, Dr Varun Sethi, Dr 
Matteo Pardini, Dr Declan T Chard, Dr Daniel J Tozer, Dr Rebecca S 
Samson, Dr Nils Muhlert.  
Drafting of the manuscript: Dr Özgür Yaldizli, Dr Matteo Pardini, Dr Declan 
T Chard.  
Critical revision of the manuscript for important intellectual content: Dr 
Özgür Yaldizli, Dr Matteo Pardini, Dr Varun Sethi, Dr Nils Muhlert, Dr 
Zheng Liu, Dr Daniel J Tozer, Dr Rebecca S Samson, Dr Claudia Wheeler-
Kingshott, Prof David H Miller, Dr Declan T Chard.  
Statistical analysis: Dr Özgür Yaldizli, Dr Matteo Pardini, Dr Declan T 
Chard.  
Administrative, technical, and material support: Dr Özgür Yaldizli, Dr 
Varun Sethi, Dr Declan T Chard.  
Study supervision: Dr Declan T Chard, Dr Claudia Wheeler-Kingshott, Prof 
Tarek Yousry, Prof David H Miller 
Table 1: Subject demographics and clinical parameters. 
Controls Patients 
RRMS SPMS Sig. (RRMS 
vs. SPMS) 
N 36 46 26 
Age (years) 41.5±12.8
5 
41.7±9.9 51.3±7.2 <0.001 
Females (%) 19(52.8) 30(65.2) 18(69.2) ns 
Disease duration 
(years) 
11±7.0 19.9±9.2 <0.001 
Median EDSS (range) 2(0-7) 6.5(4-
8.5)
<0.001 
MSFC 0.7±0.27 -
0.27±1.26 
-2.3 ±2.5 <0.001 
- PASAT 0.61±0.63 -0.13±1.0 -
0.44±1.0 
ns 
- TWT 0.51±0.10 -0.58±3.0 -5.7±6.5 <0.001 
- 9HPT 0.98±0.5 -0.09±0.6 -
0.8±1.05 
0.001 
SDMT 61.8±9.5 49.7±11.6 42.5±10 0.01 
Currently taking 
DMT(%)
28(60.9) 7(26.9) <0.001 
Legend: Continuous variables are presented as mean ± standard 
deviation. Components of the MS Functional Composite (MSFC, expressed 
as z-scores) were determined, calculated using own controls as reference 
population.  
Abbreviations: 9HPT: nine hole peg test; DMT: disease modifying 
treatment; EDSS: Expanded Disability Status Scale; PASAT: Paced 
Auditory Serial Addition Test; RRMS: relapsing–remitting multiple 
sclerosis; SPMS: secondary progressive multiple sclerosis; TWT: Timed 
25-Foot walk test, SDMT Symbol Digit Modalities Test.  
Table 2: Cortical magnetic resonance imaging measures in relapsing-
remitting and secondary-progressive multiple sclerosis compared with 
healthy control subjects 
MRI  
parameters 
Tissue Controls Patients 
RRMS SPMS Sig. (RRMS 
vs. SPMS) 
FA Extra-
lesional 
cortical GM 
0.14 
(0.01) 
0.14 
(0.02) 
0.13 
(0.01) 
ns 
Intracortical 
lesions 
- 0.20 
(0.03) 
0.21 
(0.04) 
ns 
MD Extra-
lesional 
cortical GM 
0.85 
(0.03) 
0.92 
(0.07) 
0.95 
(0.07) 
ns 
Intracortical 
lesions 
- 0.84 
(0.08) 
0.90 
(0.10) 
<0.01 
MTR Extra-
lesional 
cortical GM 
32.6 
(0.8) 
31.4 
(1.4) 
30.5 
(1.2) 
<0.05 
Intracortical 
lesions 
- 31.1 
(2.15) 
29.6 
(1.79) 
<0.05 
Counts, 
median 
(range) 
Intracortical 
lesions 
0 24.5 
(1-108) 
32.0 
(4-105) 
<0.05 
Volume Intracortical 
lesions 
0 0.47 
(0.43) 
0.70 
(0.56) 
<0.05 
BPF 0.82 (0.02) 0.80 (0.02) 0.79 (0.02) ns 
Legend: Variables are given in mean (standard deviation) unless indicated 
differently. Abbreviations: RR relapsing-remitting, SP secondary 
progressive, MS multiple sclerosis, FA fractional anisotropy, MD mean 
diffusivity, MTR magnetisation transfer ratio, GM grey matter, BPF brain 
parenchymal fraction 
Average MD is expressed in units of mm2 s-1x10-3, FA is a dimensionless 
quantity, MTR a percentage, lesion volume in mL and lesion counts in 
median and range 
Table 3: Stepwise linear regression analyses with EDSS, SDMT, and MSFC 
scores as outcome parameters and all significant variables from the 
univariate analysis as covariates.  
Clinical 
outcome 
parameter 
Significan
t 
covariates 
Standardise
d Beta 
coefficient 
Sig. Adjusted 
R-square 
SDMT MTR in extra-
lesional cortical GM 
0.424 <0.001 0.23 
PD/T2 WM lesion 
volume 
-0.269 <0.05 0.13 
MSFC MTR in extra-
lesional cortical GM 
0.407 <0.001 0.15 
EDSS MTR in extra-
lesional cortical GM 
-0.280 <0.05 0.16 
MTR 
intracortical 
lesions 
-0.344 <0.05 0.20 
Legend: Covariates included FA, MD, and MTR in extra-lesional cortical 
GM, MTR in intracortical lesions, PD/T2 WM lesion volume and brain 
parenchymal fraction.  
Results including their individual adjusted R square are demonstrated for 
significant variables only.  
Abbreviations: MSFC Multiple sclerosis functional composite, EDSS 
Expanded Disability Status Scale, SDMT Symbol Digit Modalities Test, FA 
fractional anisotropy, MD mean diffusivity, MTR magnetisation transfer 
ratio, PD proton density, GM grey matter, WM white matter, Sig. 
significance level 

Figure 1: Example of an intracortical lesion (chevron) on PSIR and 
corresponding FLAIR, MTR and DTI maps.  
Abbreviations: PSIR phase sensitive inversion recovery, FLAIR fluid 
attenuated inversion recovery, MTR magnetisation transfer ratio, b0 
diffusion tensor imaging 

Figure 2: Magnetisation transfer ratio (MTR) in intracortical lesions (ICLs) 
and extra-lesional cortical grey matter in relapsing-remitting (RR) and 
secondary-progressive (SP) MS compared with healthy control (HC) 
subjects.  
Significances *p<0.05, ***p<0.001. 
Supplement eTable 1:  
MRI acquisition parameter, all images have been aligned to the anterior 
posterior commissure line 
Dimension Acquisition 
Plane 
Resolution 
(mm) 
FOV 
(mm) 
Matrix TR 
(ms) 
TE 
(ms) 
TI 
(ms) 
Slices SENSE Time 
(mins:sec) 
T1 3D Sagittal 1x1x1 256x256 256x256  6.9  3.1  824 180  2  6:32 
PSIR 2D Axial-
oblique 
0.5x0.5x2 240x180 480x360 7301 13 400 75 - 11:26 
PD/T2 2D Axial-
oblique 
1x1x3 240x180 240x180 3500 19/85 - 50 1.7 4:01 
FLAIR 2D Axial-
oblique 
1x1x3 240x180 240x180 8000 125 2400 50 1.3 3:44 
DTI* 2D Axial-
oblique 
2x2x2 192x224 96x112 ~24000 68 -  72 3.1  ~34:00 
MTR** 3D Sagittal 1x1x1 256x256 256x256 6.4 2.7/4.3 - 180  -  26:00 
NOTE 
* High angular resolution diffusion imaging consisting of a cardiac-gated
spin-echo echo-planar imaging, 60 isotropically distributed diffusion-
weighted directions with b=1200 s/mm2, 7 non diffusion-weighted [b=0] 
volumes, TR depending on cardiac rate. 
** 3D slab-selective fast field echo sequence with two echoes was used. A 
turbo field echo readout was used, with an echo train length of four and 
turbo field echo shot interval of 32.5 ms giving a total time between 
successive MT pulses of 51.9 ms, and scan time of approximately 26 
minutes. The two echoes were averaged (thereby increasing the signal to 
noise ratio) for both the MT(on) and MT(off) data used to calculate the 
MTR. Sinc-Gaussian shaped MT pulses with flip angle of 360° and 16 ms 
duration but in total, the time between MT pulses was 51.9 ms (including 
the MT pulse duration and gradients).  
Legend: D dimensional FFE fast field echo, TR repetition time, TE echo 
time, TI inversion time, SENSE sensitivity encoding factor, FOV Field of 
view FLAIR fluid attenuated inversion recovery, DTI diffusion tensor 
imaging, MTR magnetisation transfer ratio 
Supplement eTable 2: Additional quantitative MRI measures in whole 
cortex, cortical lesions, leucocortical lesions, PD/T2 white matter lesions 
and normal-appearing white matter. 
MRI 
measure 
Tissue HCs MS Sig.
(HCs 
vs. MS) 
RRMS SPMS Sig. 
(RRMS 
vs. 
SPMS)
FA Whole cortex 0.16 
(0.01) 
0.15 
(0.01) 
<0.001 0.15 
(0.01) 
0.15 
(0.01) 
0.16 
Cortical lesions (purely 
intracortical plus GM 
part of leucocortical 
lesions) 
- 0.19 
(0.04) 
- 0.19 
(0.04) 
0.19 
(0.04) 
0.87 
Leucocortical lesions - 0.22 
(0.05) 
- 0.22 
(0.05) 
0.22 
(0.03) 
0.54 
PD/T2 WM lesions 0.31 
(0.04) 
0.30 
(0.04) 
0.36 0.30 
(0.04) 
0.29 
(0.03) 
0.50 
NAWM 0.38 
(0.01) 
0.36 
(0.03) 
<0.001 0.36 
(0.03) 
0.35 
(0.02) 
0.06 
MD Whole cortex 0.85 
(0.03) 
0.95 
(0.06) 
<0.001 0.94 
(0.07) 
0.96 
(0.06) 
0.12 
Cortical lesions (purely 
intracortical plus GM 
part of leucocortical 
lesions) 
- 0.89 
(0.09) 
- 0.87 
(0.08) 
0.92 
(0.10) 
0.035 
Leucocortical lesions - 0.91 
(0.11) 
- 0.89 
(0.10) 
0.94 
(0.12) 
0.064 
PD/T2 WM lesions 0.85 
(0.10) 
1.03 
(0.11) 
0.03 1.01 
(0.12) 
1.07 
(0.10) 
0.03 
NAWM 0.72 
(0.03) 
0.75 
(0.05) 
<0.001 0.75 
(0.05) 
0.75 
(0.06) 
0.43 
MTR Whole cortex 31.0 
(0.9) 
29.9 
(1.5) 
<0.001 29.8 
(1.4) 
28.7 
(1.1) 
0.001 
Cortical lesions (purely 
intracortical plus GM 
part of leucocortical 
lesions) 
- 30.3 
(1.7) 
- 30.6 
(1.7) 
29.8 
(1.6) 
0.04 
Leucocortical lesions - 28.7 
(3.2) 
- 29.8 
(1.4) 
28.7 
(1.1) 
0.054 
PD/T2 WM lesions 37.3 
(2.5) 
28.9 
(4.3) 
<0.001 29.0 
(3.5) 
26.3 
(3.3) 
0.02 
NAWM 39.3 
(1.1) 
38.4 
(1.3) 
<0.001 38.4 
(1.2) 
37.5 
(1.4) 
0.006 
Legend: Abbreviations NAWM normal-appearing white matter, FA 
fractional anisotropy, MD mean diffusivity, MTR magnetisation transfer 
ratio, RRMS relapsing-remitting multiple sclerosis, SPMS secondary-
progressive multiple sclerosis. 
Supplement eTable 3: Correlation between whole cortex and 
leucocortical lesion measures and clinical outcome parameter. 
EDSS MSFC SDMT 
Whole cortex 
- FA ns 0.21* 0.27* 
- MD ns -0.34** -0,43** 
- MTR -
0.40** 
0.51* 0.55** 
Leucocortical lesions 
- volume ns ns -0.34* 
- FA ns -0.22* ns 
- MD ns ns ns 
- MTR -0.27* -0.31* ns 
Legend: Values represent Spearman rho coefficients, significances are 
given as * (p<0.05), ** (p<0.01), *** (p<0.001).  
Abbreviations: EDSS Expanded Disability Status Scale score, MSFC 
Multiple sclerosis function composite score, SDMT Symbol Digit Modalities 
Test score, FA fractional anisotropy MD mean diffusivity MTR 
magnetization transfer ratio 
Supplement eTable 4: Multivariate linear regression model with 
measures of the whole cortex as predictors of clinical outcome measures 
Clinical outcome 
parameter 
Significant covariates Standardised 
Beta  
coefficient 
P-value Adjusted 
R-square 
SDMT MTR whole cortex 0.546 <0.001 0.292 
PD/T2 WM lesion volume -0.463 <0.01 0.208 
MSFC MTR whole cortex 0,419 <0.001 0.166 
EDSS MTR whole cortex -0.404 <0.01 0.154 
MTR intracortical lesions -0.349 <0.05 0.112 
Legend: Covariates included FA, MD, and MTR in whole cortex, MTR in 
intracortical lesions, PD/T2 WM lesion volume and BPF.  
Results including their individual adjusted R square are demonstrated for 
significant variables only.  
Abbreviations: MSFC Multiple sclerosis functional composite, EDSS 
Expanded Disability Status Scale, SDMT Symbol Digit Modalities Test, FA 
fractional anisotropy, MD mean diffusivity, MTR magnetization transfer 
ratio, PD proton density, WM white matter, BPF brain parenchymal 
fraction 
